



Pharmacokinetics and Pharmacodynamics of Topical Decongestants Xylometazoline and Oxymetazoline: A Literature Review

Dmytro Grebeniuk ^{a++*}, Yaroslav Hrytsun ^{b++}
and Oleg Nikulchenko ^{c#}

^a Department of Endoscopic and Cardiovascular Surgery, National Pirogov Memorial Medical University, Vinnytsya, Vinnytsia, Ukraine.

^b Department of Otorhinolaryngology, National Pirogov Memorial Medical University, Vinnytsya, Ukraine.

^c Department of Pediatric Infection Diseases, National Pirogov Memorial Medical University, Vinnytsya, Ukraine.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JOCAMR/2023/v24i3501

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/109017>

Review Article

Received: 28/08/2023

Accepted: 02/11/2023

Published: 06/11/2023

ABSTRACT

Introduction: This article provides a review and detailed analysis of scientific publications on the pharmacokinetic and pharmacodynamic characteristics of xylometazoline and oxymetazoline. Xylometazoline and oxymetazoline are two commonly used nasal decongestants used to

⁺⁺ Associate Professor;

[#] Assistant;

*Corresponding author: E-mail: doctor.svo@gmail.com;

temporarily relieve nasal congestion caused by colds, allergies, and sinusitis. Both drugs narrow blood vessels in the nasal passages, reducing edema and rhinorrhea.

Aims: The aim of the study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of xylometazoline and oxymetazoline based on a literature review.

Material and Methods: A retrospective review of literature data was performed using Scopus, Web of Science, PubMed, and ScienceDirect databases. Different keyword combinations, such as "topical decongestants", "xylometazoline", "oxymetazoline", "pharmacokinetics" and "pharmacodynamics", were used to search for information on the problem addressed. When processing search results, either the most recent publications (over the last 10 years) or the latest publications for this topic (regardless of their release) were chosen.

Results: After reviewing abstracts and getting acquainted with their full-text articles, 47 scientific sources that met the eligibility criteria were selected. Although there are minor differences between pharmacokinetics and pharmacodynamics of xylometazoline and oxymetazoline according to available literature sources, both drugs exhibit very low systemic exposure, thus reducing the number of side effects due to the lack of systemic action and producing a high local concentration of the drugs in areas of inflammation. Besides, because of its pharmacokinetic properties, xylometazoline has a faster onset of action and a shorter duration of therapeutic effect compared to oxymetazoline.

Keywords: *Topical decongestants; xylometazoline; oxymetazoline; pharmacokinetics; pharmacodynamics; review.*

1. INTRODUCTION

"Oxymetazoline and xylometazoline are two commonly used nasal decongestants that provide temporary relief for nasal congestion caused by colds, allergies, and sinusitis" [1]. "Both drugs narrow blood vessels in the nasal passages, thus reducing edema and rhinorrhea. Xylometazoline and oxymetazoline are imidazoline derivatives that act as alpha-adrenoceptor agonists" [1]. "They stimulate alpha-adrenergic receptors in the blood vessels of the nasal mucosa, which results in vasoconstriction, thus shrinking swollen nasal passages and facilitating breathing" [2-6]. "Some studies suggest that oxymetazoline is more potent and has a longer duration of action in comparison to xylometazoline" [7].

Xylometazoline demonstrates a slightly faster onset of action; its decongestant effect begins within 5–10 minutes of application [8,9]. Oxymetazoline starts working in 10 minutes [10-13]. The duration of oxymetazoline action is 8–12 hours, compared to 6–8 for xylometazoline [10,11,8,9,12,13].

The difference in the mechanism of action of both drugs comes from their pharmacokinetic and pharmacodynamic characteristics.

The aim of the study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of xylometazoline and oxymetazoline based on a literature review.

2. MATERIALS AND METHODS

A retrospective review of literature data was performed using Scopus, Web of Science, PubMed, and ScienceDirect databases. Different keyword combinations, such as "topical decongestants", "xylometazoline", "oxymetazoline", "pharmacokinetics" and "pharmacodynamics", were used to search for information on the problem addressed. When processing search results, either the most recent publications (over the last 10 years) or the latest publications for this topic (regardless of their release) were chosen. After reviewing abstracts and getting acquainted with their full-text articles, 47 scientific sources that met the eligibility criteria were selected. An overview and detailed analysis of scientific papers on the problem addressed are below.

3. RESULTS AND DISCUSSION

3.1 Pharmacokinetics

The comparison of the main pharmacokinetic properties of xylometazoline and oxymetazoline is somewhat difficult, as there exists only a limited number of papers dedicated to this topic in the scientific literature.

3.2 Absorption and Distribution

Xylometazoline and oxymetazoline are rapidly absorbed after oral or intranasal administration.

Drugs practically do not reach the systemic circulation following oral and intranasal administration.

The absolute bioavailability of xylometazoline after oral administration is about 33%, according to the literature data [14].

The results of an autoradiographic study demonstrated that the majority of ¹⁴C-xylometazoline remained in the nasal cavity after intranasal administration of ¹⁴C-xylometazoline to rats. However, a part of ¹⁴C-xylometazoline was absorbed and distributed into the tissues in a pattern similar to that observed after the intravenous administration.

At the same time, the absence of systemic effects following intranasal administration of xylometazoline to test dogs at a concentration 1000 times greater than the minimum effective dose (1,65 µg) demonstrates a very low absorption of xylometazoline [15].

The bioavailability of oxymetazoline following intranasal administration (40 µg/dose) to rats was 6,8% [16].

The peroral absorption and in vitro steady-state intestinal permeability coefficients were determined for oxymetazoline in the paper by Dowty et al. [17]. Rats were administered either an oral or intravenous dose of 91,2 µg/kg ¹⁴C-oxymetazoline to determine absorption parameters. The fraction of orally absorbed oxymetazoline was 43%.

Duzman et al. studied oxymetazoline absorption after its ocular administration in rabbits [18]. Rabbits received binocular topical applications of 50 µL of 0,025% (12,5 µg/eye) ¹⁴C-oxymetazoline. The measurements of the exposure to radioactivity in the different compartments of the eye were performed at 30 minutes, 1, 3, and 6 hours post-administration. Oxymetazoline was poorly absorbed into the cornea (0,405% of the dose was recovered at 30 minutes). Only 0,006% of the radioactive dose was present in the aqueous humor 30 minutes after drug administration, which increased to approximately 0,02% of the dose 3 and 6 hours after drug administration. Radioactivity was also low in other ocular tissues, including the choroid/retina, ciliary body, iris, lens, and vitreous humor.

The total amount of radioactivity found in all tissues was only 0,084% of the dose at 30

minutes, 0,091% at 1 hour, 0,127% at 3 hours, and 0,107% at 6 hours. The highest concentrations were found in the external ocular tissues, such as the cornea, conjunctiva, sclera, and nictitating membrane.

3.3 Metabolism and Elimination

There is practically no data on the metabolism and elimination of xylometazoline in the scientific literature. Xylometazoline undergoes extensive first-pass metabolism in the liver. It is mainly metabolized by oxidation and conjugation to form several metabolites, which are then excreted in the urine. The elimination half-life of xylometazoline is approximately 2–3 hours. Only a small amount of the drug is excreted in the feces [15].

No information on oxymetazoline metabolism in the liver was found due to its low systemic absorption and bioavailability. Mahajan et al. paper [19] studied the in vitro metabolism of oxymetazoline. As a result, the authors found 11 metabolites (M1–M11) in the post-mitochondrial supernatant fraction from homogenized tissue fractions and their microsomes supplemented with nicotinamide adenine dinucleotide phosphate (NADPH). M6 and M7 were not detected without NADPH. Only M6 had significant pharmacokinetic consequences as it affected CYP2C19 function. Researchers concluded that such low concentrations of the drug in the systemic circulation were not clinically significant.

In the study conducted in rabbits, radioactivity excreted in the urine during the first 48 hours was 23% for intranasal ¹⁴C-oxymetazoline administration and 48% for IV ¹⁴C-oxymetazoline administration [18].

3.4 Pharmacodynamics

Nasal obstruction induced by acute infective or allergic rhinitis is characterized by swelling of the nasal mucosa and rhinorrhea due to the dilation and increased permeability of cavernous venous plexuses and their overfilling with blood [20].

The vascular smooth muscle of the nasal mucosa is believed to be the only tissue that has the ability to contract in response to vasoconstrictor sympathomimetic agents, imidazole derivatives (oxymetazoline) [21]. Previous studies demonstrated that α1- and α2-adrenoceptors were present in the nasal mucosa of dogs [22], pigs [23,24], and humans [25,26],

and their stimulation led to vasoconstriction in the nasal mucosa [23,26,24], whereas stimulation of β -adrenergic receptors had the opposite effect (vasodilation) [27,28].

Xylometazoline is a direct-acting alpha-adrenergic agonist with affinity to both α 1- and α 2-adrenoceptors [1]. Stimulation of α 1-adrenoceptors through Gq/11-proteins leads to the activation of phospholipase C, generation of inositol-1,4,5-triphosphate, which facilitates the release of Ca^{2+} from the sarcoplasmic reticulum. Ca^{2+} interaction with calmodulin activates myosin light chain kinase. Phosphorylation of the myosin light chain and their interaction with actin result in smooth muscle contraction [29,30]. At the same time, activation of α 2-adrenoceptors through Gq/11-proteins inhibits adenylyl cyclases and, therefore, decreases cAMP production and protein kinase A activity. The inhibitory effect of protein kinase A on myosin light chain kinase is decreased. Phospholamban inhibits sarcoplasmic reticulum Ca^{2+} -ATPase, which transports Ca^{2+} from cytoplasm to sarcoplasmic reticulum, thus increasing Ca^{2+} concentration in the cytoplasm and resulting in smooth muscle and vessel contraction [31,32,33,30]. The extracellular fluid that contributes to congestion and rhinorrhea, as well as nasal mucosa, are reduced as a result of vasoconstriction and a decrease in the blood flow to cavernous venous plexus vessels, which facilitates nasal breathing.

“Messenger ribonucleic acid (mRNA) expression in the nasal mucosa of the six α -adrenoceptor subtypes was explored in one of the studies” [1]. “Furthermore, the affinity and potency of the imidazolines oxymetazoline and xylometazoline at these α -adrenoceptor subtypes were examined in transfected HEK293 cells (Human Embryonic Kidney 293). The rank order of mRNA levels of α -adrenoceptor subtypes in human nasal mucosa was: α 2A > α 1A > α 2B > α 1D > α 2C > α 1B. Oxymetazoline and xylometazoline showed a greater affinity for the most α -adrenoceptor subtypes than adrenaline and noradrenaline. Compared to xylometazoline, oxymetazoline displayed a significantly higher affinity for α 1A and also exhibited a lower affinity for α 2B-adrenoceptors. In functional studies in which adrenoceptor-mediated Ca^{2+} signals were measured, both oxymetazoline and xylometazoline displayed full antagonist properties at α 2B-adrenoceptors but oxymetazoline was more potent than xylometazoline. Besides, oxymetazoline was also

an α 1A-adrenoceptor partial agonist; however, its potency and affinity were low” [1].

The highest affinity of oxymetazoline at α 1A-adrenoceptors was confirmed in the study by Horie et al. [34].

“The effect of topical oxymetazoline hydrochloride on the blood flow of the nasal and sinus mucosa of the rabbits measured by laser-Doppler flowmetry was studied in another research. The results of the study demonstrated that oxymetazoline induced a dose-dependent decrease in nasal mucosal blood flow. Furthermore, oxymetazoline induced a dose-dependent decrease in mucosal blood flow in the maxillary sinus following intranasal administration. A vasoconstrictor effect of oxymetazoline on the arteries penetrating the maxillary sinus ostium is a possible explanation” [35].

“Besides, the Bende et al. study showed that oxymetazoline contributed to a decrease in vascular permeability of the nasal mucosa in rabbits after provocation with leukotriene B₄” [36].

Increased nitric oxide (NO) levels in exhaled air are observed in patients with upper respiratory tract infections [37]. Furthermore, elevated nitric oxide metabolite levels are present in the nasal lavage fluid of patients allergic to house dust mites [38], and nasal polyps contain higher levels of NO synthase (NOS) than normal nasal mucosa [39]. “NOS plays a role in the regulation of vascular permeability and nasal cavity volume” [40,41]. Also, NO, upon reacting with the superoxide anion radical and producing peroxynitrite, acts as a potent cytotoxic effector molecule [42]. Both functions may lead to nasal inflammation and indicate the involvement of NO in the pathogenesis of upper respiratory tract inflammation.

Suggesting that the NO system is involved in the pathogenesis of upper respiratory tract inflammation, the effects of xylometazoline on NOS and inducible NO (iNOS) activity and expression were investigated *in vitro*. Besides, the direct scavenging properties of xylometazoline towards nitric oxide were studied.

“Xylometazoline was reported to have a dose-dependent inhibitory effect on total iNOS activity determined by nitrite/nitrate formation in the Griess test. This effect was found to be due to an

inhibition of induction of the enzyme rather than inhibition of enzyme activity. Inhibition of constitutive NOS (cNOS) was moderate and had the same mechanism as inhibition of enzymatic iNOS activity. No direct scavenging properties of xylometazoline towards NO were detected" [43].

"As cNOS plays a crucial role in physiological processes and iNOS may exacerbate the inflammatory process, the pharmacological effect on the nitric oxide-generating system should be focused on the inhibition of iNOS alone. The specific characteristics of xylometazoline in vitro suggest its suitability for this application and may indicate an additional beneficial effect in the treatment of upper respiratory tract inflammation" [43].

"The antioxidant effects of xylometazoline were investigated by measuring the inhibition of microsomal lipid peroxidation and hydroxyl radical activity" [42]. It was reported that xylometazoline did not influence microsomal lipid peroxidation but significantly decreased hydroxyl radical levels. The mechanism of hydroxyl radical absorbance is still unclear. As oxidants play a role in tissue damage in inflammation, it is assumed that xylometazoline may have a beneficial effect thanks to its antioxidant effects in the topical treatment of nasal inflammation.

The ability of oxymetazoline to model pro- and anti-inflammatory and oxidative stress responses was evaluated in cell-free systems, including 5-lipoxygenase (5-LO) as proinflammatory and 15-lipoxygenase (15-LO) as anti-inflammatory enzymes. The oxidation of methionine by agglomerates of ultrafine carbon particles (UCPs), indicating oxidative stress, was studied. In a cellular system using canine alveolar macrophages, the impact of oxymetazoline on phospholipase A2 (PLA2) activity, respiratory burst, and synthesis of prostaglandin E2 (PGE2), 15(S)-hydroxy-eicosatetraenoic acid (15-HETE), leukotriene B(4) (LTB4), and 8-isoprostane was measured in the absence and presence of UCP or opsonized zymosan as particulate stimulants. In cell-free systems, oxymetazoline (0.4-1 mM) inhibited 5-LO but not 15-LO activity and did not alter UCP-induced oxidation of methionine.

"In alveolar macrophages oxymetazoline induced PLA2 activity and 15-HETE at 1 mM, enhanced PGE2 at 0,1 mM, strongly inhibited LTB4 and respiratory burst at 0,4/0,1 mM ($p < 0,05$), but did not affect 8-isoprostane formation. Oxymetazoline did not alter UCP-induced PLA2

activity and PGE2 and 15-HETE formation in alveolar macrophages but inhibited UCP-induced LTB4 formation and respiratory burst at 0,1 mM and 8-isoprostane formation at 0,001 mM. In opsonized zymosan-stimulated alveolar macrophages, oxymetazoline inhibited LTB4 formation and respiratory burst (0,1 mM)" [44].

"Thus, in canine alveolar macrophages, oxymetazoline suppressed proinflammatory reactions including 5-LO activity, LTB4 formation, and respiratory burst, and prevented oxidative stress, whereas PLA2 activity and synthesis of immune-modulating PGE2 and 15-HETE were not affected" [44].

Schoeffter et al. [45] in their study, using American opossum kidney epithelium cells, demonstrated that oxymetazoline was a potent agonist at 5-hydroxytryptamine (5-HT, serotonin) 1A, 1B, and 1D, and a partial agonist at 5-HTP 1C receptors.

Another study explored the effect of oxymetazoline on isolated rat's tracheal smooth muscles. A rat trachea of 5 mm in length was immersed in 30ml Krebs-Ringer solution at 37°C. Administration of oxymetazoline caused significant tracheal relaxation in a dose-dependent manner, even in the presence of a cholinergic agent. The effects of oxymetazoline on the basal tension of the trachea were insignificant. The study indicated that high concentrations of oxymetazoline might actually antagonize cholinergic receptors of the trachea [46].

The other study [47] showed that oxymetazoline following intravenous administration at 0,2-1,7 mmol/kg decreased basal gastric motor activity. After stimulation of the motility by insulin (5 IU/rat, i.v.), both clonidine (1,9-3,8 mmol/kg, i.v.) and oxymetazoline (0,1-3,4 mmol/kg, i.v.) inhibited the gastric motor activity. However, while the effect of clonidine was antagonized by the non-selective α_2 -adrenoceptor antagonist yohimbine (5 mmol/kg, i.v.) and the α_2 -adrenoceptor selective antagonist BRL 44408 (3 mmol/kg, i.v.), the effect of oxymetazoline was only partially affected. Prazosin (α_1 - and α_2 -adrenoceptor antagonist, 0,07-0,28 mmol/kg, i.v.) also failed to reverse the effect of oxymetazoline. Furthermore, when gastric motility was stimulated peripherally by activation of postsynaptic cholinergic muscarinic receptors by the combination of carbachol (0,14 mmol/kg, i.v.) and hexamethonium (37 mmol/kg, i.v.), clonidine (3,8 mmol/kg, i.v.) failed to affect the increased

motor activity; however, oxymetazoline (0,8-3,4 mmol/kg, i.v.) exerted a pronounced inhibition. These results suggest that different mechanisms may be involved in the inhibitory effects of clonidine and oxymetazoline; while clonidine reduces gastric motility by activating presynaptic α 2-adrenoceptors, a postsynaptic component in the effect of oxymetazoline has also been observed.

4. CONCLUSION

Although, according to the available scientific data, there are minor differences between the pharmacokinetics and pharmacodynamics of xylometazoline and oxymetazoline. Both drugs have very low systemic exposure, while creating high local concentrations in areas of inflammation. Such properties of these drugs allow them to achieve high efficiency with a small number of systemic side effects.

In addition, due to its pharmacokinetic properties, xylometazoline has a faster onset of action and a shorter duration of therapeutic effect compared to oxymetazoline.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENTS

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaiquin M, Ramseger R, Bönnisch H. Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. *Fundam Clin Pharmacol*. 2010 Dec;24(6):729-39. DOI: 10.1111/j.1472-8206.2009.00805.x PMID: 20030735.

2. Deckx L, De Sutter AI, Guo L, Mir NA, van Driel ML. Nasal decongestants in monotherapy for the common cold. *Cochrane Database Syst Rev*. 2016 Oct 17;10(10):CD009612. DOI: 10.1002/14651858.CD009612.pub2 PMID: 27748955; PMCID: PMC6461189.
3. Jones RS. Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management. *J Clin Med*. 2021 Mar 15;10(6):1212. DOI: 10.3390/jcm10061212 PMID: 33803990; PMCID: PMC7998280.
4. Joshi KS, Ho VWQ, Smith ME, Tysome JR. The effect of topical xylometazoline on Eustachian tube function. *J Laryngol Otol*. 2020 Jan;134(1):29-33. DOI: 10.1017/S0022215120000158 Epub 2020 Jan 22. PMID: 31964436.
5. Macmillan AJ, Phoon KM, Edefe O. Safety of topical administration of nasal decongestants and vasoconstrictors in paediatric nasal surgery - A systematic review. *Int J Pediatr Otorhinolaryngol*. 2022 Feb;153:111010. DOI: 10.1016/j.ijporl.2021.111010 Epub 2021 Dec 17. PMID: 34942425.
6. Reid JW, Rotenberg BW, Sowerby LJ. Contemporary decongestant practices of Canadian otolaryngologists for endoscopic sinus surgery. *J Otolaryngol Head Neck Surg*. 2019 Mar 18;48(1):15. DOI: 10.1186/s40463-019-0337-8 PMID: 30885260; PMCID: PMC6421656.
7. Eskiizmir G, Hirçin Z, Ozyurt B, Unlü H. A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects. *Eur J Clin Pharmacol*. 2011 Jan;67(1):19-23. DOI: 10.1007/s00228-010-0941-z Epub 2010 Nov 11. PMID: 21069518.
8. Hillier K, Jewell R. Oxymetazoline. *xPharm: The Comprehensive Pharmacology Reference*. 2007;1-6. DOI: 10.1016/b978-008055232-3.62349-9
9. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 5709, Xylometazoline; [cited 2023 Sept. 23]. Available: <https://pubchem.ncbi.nlm.nih.gov/compound/Xylometazoline>
10. Bylund D. Xylometazoline. *Reference Module in Biomedical Sciences*, 1-3. DOI: 10.1016/b978-0-12-801238-3.98854-8

11. Druce HM, Ramsey DL, Karnati S, Carr AN. Topical nasal decongestant oxymetazoline (0.05%) provides relief of nasal symptoms for 12 hours. *Rhinology*. 2018 Dec 1;56(4):343-350. DOI: 10.4193/Rhin17.150 PMID: 29785414.
12. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 4636, Oxymetazoline; [cited 2023 Sept. 23]. Available: <https://pubchem.ncbi.nlm.nih.gov/compound/Oxymetazoline>
13. Pritchard S, Glover M, Guthrie G, Brum J, Ramsey D, Kappler G, et al. Effectiveness of 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray in the treatment of objective nasal congestion demonstrated to 12 h post-administration by magnetic resonance imaging. *Pulm Pharmacol Ther*. 2014 Feb;27(1):121-6. DOI: 10.1016/j.pupt.2013.08.002 Epub 2013 Aug 27. PMID: 23988443.
14. Patel P, Singla J. Xylometazoline [Internet]. *MedicalDialogues.in*; 2023 [cited 2023 Sep 24]. Available: <https://medicaldialogues.in/generics/xylometazoline-2723804>
15. The Heads of medicines [Internet]. Mutual Recognition Index: Final PAR Scientific discussion – Klarigen; 2014. Available: <https://pubchem.ncbi.nlm.nih.gov/compound/Oxymetazoline>.
16. Hayes FJ, Baker TR, Dobson RL, Tsueda MS. Rapid liquid chromatographic-mass spectrometric assay for oxymetazoline in whole rat blood. *J Chromatogr A*. 1995 Feb 10;692(1-2):73-81. DOI: 10.1016/0021-9673(94)00630-r PMID: 7719462.
17. Dowty ME, Dietsch CR. Improved prediction of in vivo peroral absorption from in vitro intestinal permeability using an internal standard to control for intra- and inter-rat variability. *Pharm Res*. 1997 Dec;14(12):1792-7. DOI: 10.1023/a:1012148300807 PMID: 9453070.
18. Duzman E, Anderson J, Vita JB, Lue JC, Chen CC, Leopold IH. Topically applied oxymetazoline. Ocular vasoconstrictive activity, pharmacokinetics, and metabolism. *Arch Ophthalmol*. 1983 Jul;101(7):1122-6. DOI:10.1001/archopht.1983.01040020124022 PMID: 6347152.
19. Mahajan MK, Uttamsingh V, Daniels JS, Gan LS, LeDuc BW, Williams DA. In vitro metabolism of oxymetazoline: Evidence for bioactivation to a reactive metabolite. *Drug Metab Dispos*. 2011 Apr;39(4):693-702. DOI: 10.1124/dmd.110.036004 Epub 2010 Dec 21. PMID: 21177487.
20. Druce HM, Bonner RF, Patow C, Choo P, Summers RJ, Kaliner MA. Response of nasal blood flow to neurohormones as measured by laser-Doppler velocimetry. *J Appl Physiol Respir Environ Exerc Physiol*. 1984 Oct;57(4):1276-83. DOI: 10.1152/jappl.1984.57.4.1276 PMID: 6389454.
21. Ichimura K, Jackson RT. Evidence of alpha 2-adrenoceptors in the nasal blood vessels of the dog. *Arch Otolaryngol*. 1984 Oct;110(10):647-51. DOI: 10.1001/archotol.1984.00800360019004 PMID: 6148058.
22. Berridge TL, Roach AG. Characterization of alpha-adrenoceptors in the vasculature of the canine nasal mucosa. *Br J Pharmacol*. 1986 Jun;88(2):345-54. DOI: 10.1111/j.1476-5381.1986.tb10210.x PMID: 2873858; PMCID: PMC1916819.
23. Corboz MR, Varty LM, Rizzo CA, Mutter JC, Rivelli MA, Wan Y, et al. Pharmacological characterization of alpha 2-adrenoceptor-mediated responses in pig nasal mucosa. *Auton Autacoid Pharmacol*. 2003 Aug;23(4):208-19. DOI: 10.1111/j.1474-8673.2003.00298.x PMID: 15084187.
24. Lacroix JS, Lundberg JM. Sympathetic vascular control of the pig nasal mucosa: adrenoceptor mechanisms in blood flow and volume control. *Br J Pharmacol*. 1989 Aug;97(4):1075-84. DOI: 10.1111/j.1476-5381.1989.tb12564.x PMID: 2529015; PMCID: PMC1854604.
25. Andersson KE, Bende M. Adrenoceptors in the control of human nasal mucosal blood flow. *Ann Otol Rhinol Laryngol*. 1984 Mar-Apr;93(2 Pt 1):179-82. DOI: 10.1177/000348948409300216 PMID: 6201119.
26. Corboz MR, Rivelli MA, Varty L, Mutter J, Cartwright M, Rizzo CA, Eckel SP, Anthes JC, Hey JA. Pharmacological characterization of postjunctional alpha-

- adrenoceptors in human nasal mucosa. *Am J Rhinol.* 2005 Sep-Oct;19(5):495-502. PMID: 16270605.
27. Lacroix JS, Kurt AM, Auberson S, Bretton C. Beta-adrenergic mechanisms in the nasal mucosa vascular bed. *Eur Arch Otorhinolaryngol.* 1995;252(5):298-303. DOI: 10.1007/BF00185393 PMID: 7576588.
28. Lung MA, Phipps RJ, Wang JC, Widdicombe JG. Control of nasal vasculature and airflow resistance in the dog. *J Physiol.* 1984 Apr;349:535-51. DOI: 10.1113/jphysiol.1984.sp015172 PMID: 6204040; PMCID: PMC1199353.
29. Docherty JR. Subtypes of functional alpha1- and alpha2-adrenoceptors. *Eur J Pharmacol.* 1998 Nov 13;361(1):1-15. DOI: 10.1016/s0014-2999(98)00682-7 PMID: 9851536.
30. Mathiazhagan S, Anand S, Parthiban R. Alpha Adrenergic Receptors: A Brief Perspective. *IOSR Journal of Dental and Medical Sciences.* 2013;7(4):16-19.
31. Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K, Kobilka BK, Hein L. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. *Mol Pharmacol.* 1999 Jul;56(1):154-61. DOI: 10.1124/mol.56.1.154 PMID: 10385696.
32. Starke K. Presynaptic autoreceptors in the third decade: focus on alpha2-adrenoceptors. *J Neurochem.* 2001 Aug;78(4):685-93. DOI: 10.1046/j.1471-4159.2001.00484.x PMID: 11520889.
33. Kubista H, Boehm S. Molecular mechanisms underlying the modulation of exocytotic noradrenaline release via presynaptic receptors. *Pharmacol Ther.* 2006 Oct;112(1):213-42. DOI: 10.1016/j.pharmthera.2006.04.005 Epub 2006 May 30. PMID: 16730801.
34. Horie K, Obika K, Foglar R, Tsujimoto G. Selectivity of the imidazoline alpha-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha 1-adrenoceptor subtypes. *Br J Pharmacol.* 1995 Sep;116(1):1611-8. DOI: 10.1111/j.1476-5381.1995.tb16381.x PMID: 8564227; PMCID: PMC1908909.
35. Akerlund A, Arfors KE, Bende M, Intaglietta M. Effect of oxymetazoline on nasal and sinus mucosal blood flow in the rabbit as measured with laser-Doppler flowmetry. *Ann Otol Rhinol Laryngol.* 1993 Feb;102(2):123-6. DOI: 10.1177/000348949310200209 PMID: 8427497.
36. Bende M, Hansell P, Intaglietta M, Arfors KE. Effect of oxymetazoline nose drops on vascular permeability of the nasal mucosa in the rabbit after provocation with leukotriene B4. *ORL J Otorhinolaryngol Relat Spec.* 1992;54(5):270-4. DOI: 10.1159/000276313 PMID: 1336840.
37. Kharitonov SA, Yates D, Barnes PJ. Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. *Eur Respir J.* 1995 Feb;8(2):295-7. DOI: 10.1183/09031936.95.08020295 PMID: 7538934.
38. Garrelds IM, van Amsterdam JG, de Graaf-in't Veld C, Gerth van Wijk R, Zijlstra FJ. Nitric oxide metabolites in nasal lavage fluid of patients with house dust mite allergy. *Thorax.* 1995 Mar;50(3):275-9. DOI: 10.1136/thx.50.3.275 PMID: 7660342; PMCID: PMC1021192.
39. Ramis I, Lorente J, Roselló-Catafau J, Quesada P, Gelpí E, Bulbena O. Differential activity of nitric oxide synthase in human nasal mucosa and polyps. *Eur Respir J.* 1996 Feb;9(2):202-6. DOI: 10.1183/09031936.96.09020202 PMID: 8777951.
40. Rinder J, Lundberg JM. Nasal vasoconstriction and decongestant effects of nitric oxide synthase inhibition in the pig. *Acta Physiol Scand.* 1996 Jun;157(2):233-44. DOI: 10.1046/j.1365-201X.1996.509246000.x PMID: 8800364.
41. Imada M, Iwamoto J, Nonaka S, Kobayashi Y, Unno T. Measurement of nitric oxide in human nasal airway. *Eur Respir J.* 1996 Mar;9(3):556-9. DOI: 10.1183/09031936.96.09030556 PMID: 8730019.
42. Westerveld GJ, Scheeren RA, Dekker I, Griffioen DH, Voss HP, Bast A. Anti-oxidant actions of oxymethazoline and xylomethazoline. *Eur J Pharmacol.* 1995 Sep 15;291(1):27-31. DOI: 10.1016/0922-4106(95)90185-x PMID: 8549644.
43. Westerveld GJ, Voss HP, van der Hee RM, de Haan-Koelewijn GJ, den Hartog GJ,

- Scheeren RA, Bast A. Inhibition of nitric oxide synthase by nasal decongestants. Eur Respir J. 2000 Sep;16(3):437-44.
DOI: 10.1034/j.1399-3003.2000.016003437.x
PMID: 11028657.
44. Beck-Speier I, Dayal N, Karg E, Maier KL, Schumann G, Semmler M, Koelsch SM. Oxymetazoline inhibits proinflammatory reactions: Effect on arachidonic acid-derived metabolites. J Pharmacol Exp Ther. 2006 Feb;316(2):843-51.
DOI: 10.1124/jpet.105.093278
Epub 2005 Oct 12. PMID: 16221739.
45. Schoeffter P, Hoyer D. Interaction of the alpha-adrenoceptor agonist oxymetazoline with serotonin 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1C} and 5-HT_{1D} receptors. Eur J Pharmacol. 1991 Apr 17;196(2):213-6.
DOI: 10.1016/0014-2999(91)90432-p
PMID: 1678720.
46. Wang HW, Wu CC. Effects of oxymetazoline on isolated rat's tracheal smooth muscle. Eur Arch Otorhinolaryngol. 2008 Jun;265(6):695-8.
DOI: 10.1007/s00405-007-0509-4
PMID: 17978828.
47. Zádori ZS, Shujaa N, Fülöp K, Dunkel P, Gyires K. Pre- and postsynaptic mechanisms in the clonidine- and oxymetazoline-induced inhibition of gastric motility in the rat. Neurochem Int. 2007 Oct;51(5):297-305.
DOI: 10.1016/j.neuint.2007.06.027
Epub 2007 Jun 30. PMID: 17664022.

© 2023 Grebeniuk et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/109017>